Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial
2024; Springer Nature; Volume: 47; Issue: 9 Linguagem: Inglês
10.1038/s41440-024-01725-4
ISSN1348-4214
AutoresAtsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Hisako Yoshida, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node, Junya Ako, Hirohisa Amano, Itaru Hisauchi, Yumi Ikehara, Hideaki Jinnouchi, Yoshiyuki Kawano, Kazuo Kimura, Akira Kurozumi, Takaaki Kusumoto, Noritaka Machii, Tatsuya Maruhashi, Yasushi Matsuzawa, Hirofumi Misu, Manabu Narisawa, Tsuguhito Ota, Jun‐ichi Oyama, Masashi Sakuma, Kazuki Shiina, Kosuke R. Shima, Seigo Sugiyama, Kunihiro Suzuki, Naohiko Takahashi, Yasuhiko Takemoto, Yumie Takeshita, Hiroshi Tamaki, Kenichi Tanaka, Akira Tamura, Keiichi Torimoto, Minako Yamaoka‐Tojo, Hiroki Uehara, Fumi Uemura, Ken Yamakawa, Kunio Yufu,
Tópico(s)Diabetes Management and Research
Referência(s)